Shoiab Bukhari

Shoiab Bukhari

Auto-generated profile, based on publicly available information

Shoiab Bukhari

Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
AAAnca D Askanase
Anca D Askanase
RSRuijiang Song
Ruijiang Song
SBShoiab Bukhari
Shoiab Bukhari
MDMatthew Dragovich
Matthew Dragovich
AMAdam Mor
Adam Mor
Signaling lymphocyte activation molecule family member 6 (SLAMF6) is a T cell co-receptor. Previously, we showed that SLAMF6 clustering was required for T cell activation. To better understand the relationship between SLAMF6 location and function and to evaluate the role of SLAMF6 as a therapeutic target, we investigated how its compartmentalization on the cell surface affects T cell functions. We used biochemical and co-culture assays to show that T cell activity is enhanced when SLAMF6 colocalizes with the CD3 complex. Mechanistically, co-immunoprecipitation analysis revealed the SLAMF6-interacting proteins to be those essential for signaling downstream of T cell receptor, suggesting the two receptors share downstream signaling pathways. Bispecific anti-CD3/SLAMF6 antibodies, designed to promote SLAMF6 clustering with CD3, enhanced T cell activation. Meanwhile, anti-CD45/SLAMF6 antibodies inhibited SLAMF6 clustering with T cell receptor, likely because of the steric hindrance, but nevertheless enhanced T cell activation. We conclude that SLAMF6 bispecific antibodies have a role in modulating T cell responses, and future work will evaluate the therapeutic potential in tumor models.

21 March 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MPMatthieu Paiola
Matthieu Paiola
DPDaniel M. Portnoy
Daniel M. Portnoy
LHLuke Yi Hao
Luke Yi Hao
SBShoiab Bukhari
Shoiab Bukhari
RWRobert Winchester
Robert Winchester
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
Objective: Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, but they can also lead to immune-related adverse events (irAEs), including inflammatory arthritis. Understanding the risk factors and underlying mechanisms of irAE pathogenesis is crucial for optimal patient management. Increasing evidence suggests that ICI-mediated activation of tissue-resident memory T cells (T RM ) significantly eliminates cancer cells and is associated with irAE-related colitis and dermatitis. However, it remains unknown why the development of these irAEs is restricted to a subset of patients. We hypothesized that osteoarthritis (OA) associated tissue damage and chronic inflammation lead to the recruitment and differentiation of joint T RM cells, predisposing individuals to ICI-induced arthritis. Methods: Using a comprehensive approach, we compared the prevalence of OA in patients with irAE-arthritis to those with irAE non-arthritis and those without irAEs. Additionally, we used advanced immunophenotyping techniques to characterize T-cell populations in the blood and synovial fluid of patients with OA and irAE-arthritis. Results: Our findings revealed a significantly higher prevalence of OA in patients who developed irAE-arthritis than controls. Furthermore, the multivariable analysis identified OA, body mass index, and smoking as independent risk factors for the development of irAE-arthritis. T RM cells expressing programmed cell death protein-1 (PD-1) were the predominant synovial T cells in OA joints. These cells were directly targeted by ICIs, resulting in an inflammatory immune response and the transition from OA to irAE-arthritis. Conclusion: This study, the first of its kind, identifies OA as a significant risk factor for irAEarthritis. It reveals a potential mechanism by which ICIs activate PD-1-positive T RM cells in OA joints, resulting in tissue inflammation and irAE-arthritis. This research could significantly enhance the management and treatment of patients with cancer receiving ICIs.

4 January 2021 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
AAAsif Amin
Asif Amin
TMTaseem A. Mokhdomi
Taseem A. Mokhdomi
SBShoiab Bukhari
Shoiab Bukhari
ZWZubair Wani
Zubair Wani
NCNAVEED ANJUM CHIKAN
NAVEED ANJUM CHIKAN
RQRaies A Qadri
Raies A Qadri

27 September 2013 in Journal of Crop Science and Biotechnology
Verified
Journal Article
Closed access
PDF file
JIJavid IqbaLMzr
Javid IqbaLMzr
NANazeer Ahmed
Nazeer Ahmed
TMTassem Ahmad Mokhdomi
Tassem Ahmad Mokhdomi
AWAsrar Hussain Wafai
Asrar Hussain Wafai
SWSajad Hassan Wani
Sajad Hassan Wani
RQRaies A Qadri
Raies A Qadri

18 May 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
AAAsif Amin
Asif Amin
SBShoiab Bukhari
Shoiab Bukhari
TMTaseem A Mokhdomi
Taseem A Mokhdomi
NANaveed Anjum
Naveed Anjum
AWAsrar H Wafai
Asrar H Wafai
RQRaies A Qadri
Raies A Qadri
Cancer loci comprise heterogeneous cell populations with diverse cellular secretions. Therefore, disseminating cancer-specific or cancer-associated protein antigens from tissue lysates could only be marginally correct, if otherwise not validated against precise standards. In this study, 2DE proteomic profiles were examined from lysates of 13 lung-adenocarcinoma tissue samples and matched against the A549 cell line proteome. A549 matched-cancer-specific hits were analyzed and characterized by MALDI-TOF/MS. Comparative analysis identified a total of 13 protein spots with differential expression. These proteins were found to be involved in critical cellular functions regulating pyrimidine metabolism, pentose phosphate pathway and integrin signaling. Gene ontology based analysis classified majority of protein hits responsible for metabolic processes. Among these, only a single non-predictive protein spot was found to be a cancer cell specific hit, identified as Armadillo repeat-containing protein 8 (ARMC8). Pathway reconstruction studies showed that ARMC8 lies at the centre of cancer metabolic pathways. The findings in this report are suggestive of a regulatory role of ARMC8 in control of proliferation and differentiation in lung adenocarcinomas.

1 July 2013 in Pharmacognosy Journal
Verified
Journal Article
Closed access
AAAsif Amin
Asif Amin
SWSajad H. Wani
Sajad H. Wani
TMTaseem A. Mokhdomi
Taseem A. Mokhdomi
SBShoiab Bukhari
Shoiab Bukhari
AWAsrar H. Wafai
Asrar H. Wafai
RQRaies A Qadri
Raies A Qadri